English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduBiognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomics biomarkers.
Tag: Lung Cancer
Mount Sinai Study Calls for Major Changes in the Way People With Comorbidities Are Selected by Physicians for Lung Cancer Screening
A Medicare policy requiring primary care providers (PCPs) to share in the decision-making with patients on whether to proceed with lung cancer screening is fraught with confusion and lack of evidence-based information, and may actually be undermining the purpose for which it was created, Mount Sinai researchers say.
MD Anderson Research Highlights for March 20, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
NCCN Updates Treatment Recommendations for Breast, Colorectal, Lung, and other Cancer Types Based on Emerging Evidence
Recent NCCN Guidelines updates—along with the supporting evidence—will be presented during the NCCN 2024 Annual Conference held in Orlando, Florida April 5-7, and simultaneously online. Visit NCCN.org/conference to learn more and register.
A self-driving needle steers through living lung tissue
The lungs are one of the most difficult organs for physicians to navigate with a conventional bronchoscope. To overcome these limitations, a team of NIH-funded researchers built a compact robotic system that can autonomously steer a flexible needle around these anatomical obstacles within the lungs of live animals.
Study unravels the earliest cellular genesis of lung adenocarcinoma
Researchers at The University of Texas MD Anderson Cancer Center built a new atlas of lung cells, uncovering new cellular pathways and precursors in the development of lung adenocarcinoma, the most common type of lung cancer. These findings, published today in Nature, open the door for development of new strategies to detect or intercept the disease in its earliest stages.
Biomarker-directed combination effective in immunotherapy-resistant lung cancer
A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study led by a researcher from The University of Texas MD Anderson Cancer Center.
Why a Targeted Therapy Is Better Than Immunotherapy For Some Patients With Inoperable Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC), with an epidermal growth factor receptor (EGFR) mutation, tends not to respond well to immunotherapy treatments, including durvalumab. However, Yale Cancer Center (YCC) researchers recently reported in the Journal of Thoracic Oncology that the targeted therapy osimertinib, when administered after chemotherapy and radiation, is associated with significantly improved progression-free survival (living without the cancer worsening).
Exposure to Even Moderate Levels of Radon Linked to Increased Risk of Stroke
Radon is the second leading cause of lung cancer. Now a new study has found exposure to this invisible, odorless gas is also linked to an increased risk of stroke.
Breakthrough Research Identifies Predictors of Venous Thromboembolism after Pulmonary Resection for Lung Cancer
In patients who undergo pulmonary resection for lung cancer, a major potential postoperative complication is venous thromboembolism (VTE)—a condition that develops when a blood clot forms in a vein—which can lead to part of the clot breaking off and lodging in the lung, resulting in a pulmonary embolism (PE).
Pathologic Scoring Shows Promise for Assessing Lung Tumor Therapy Response
A new pathologic scoring system that accurately assesses how much lung tumor is left after a patient receives presurgical cancer treatments can be used to predict survival, according to new research led by investigators at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center and the Mark Foundation Center for Advanced Genomics and Imaging at the Johns Hopkins University.
American Cancer Society Updates Lung Cancer Screening Guideline: Nearly Five Million U.S. Adults who Smoke and Formerly Smoked Now Recommended for Testing
The American Cancer Society releasesan update of its lung cancer screening guideline to help reduce the number of people dying from the disease due to smoking history.
New Study Shows Adults Treated for Non-Small Cell Lung Cancer Vulnerable to Hazards of Wildfires
New research by scientists at the American Cancer Society and the University of California, San Francisco, shows individuals in the United States undergoing radiotherapy for non-small cell lung cancer who are exposed to wildfires near the treating facility have worse overall survival than unexposed individuals.
Antibody-drug conjugate helps patients with metastatic non-small cell lung cancer live longer, delaying disease progression
Treatment with datopotamab deruxtecan (Dato-DXd), a novel Trop-2 directed antibody-drug conjugate, was found to significantly improve progression-free survival in patients with metastatic non-small cell lung cancer, an improvement that was primarily driven by patients with non-squamous tumors.
Common chemotherapy drugs don’t work like doctors thought, with big implications for drug discovery
A new study from the University of Wisconsin–Madison suggests that chemotherapy may not be reaching its full potential, in part because researchers and doctors have long misunderstood how some of the most common cancer drugs actually ward off tumors.
Lung cancer outcomes significantly improved with immunotherapy-based treatment given before and after surgery
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to results of a Phase III trial reported by researchers at The University of Texas MD Anderson Cancer Center.
MEDSIR presents the results of three new studies at ESMO 2023: LUPER, focusing on lung cancer, and two translational studies of PHERGain in breast cancer
MEDSIR, a company specializing in the strategic design of independent clinical research, today presented the results of three new studies at the European Society for Medical Oncology (ESMO 2023).
ESMO: Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer
Perioperative immunotherapy plus neoadjuvant chemotherapy significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC) compared to chemotherapy alone. Results from the Phase III CheckMate 77T study were presented today at the 2023 European Society of Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center.
MD Anderson Research Highlights: ESMO 2023 Special Edition
This special edition features upcoming oral presentations by MD Anderson researchers at the 2023 European Society for Medical Oncology (ESMO) Congress focused on clinical advances across a variety of cancer types.
Cancer researchers awarded $4.6 million to advance liquid biopsy test for early lung cancer detection
A team of investigators from the UCLA Jonsson Comprehensive Cancer Center and the UCLA School of Dentistry received a five-year $4.6 million grant from the National Cancer Institute to develop and improve liquid biopsy technologies for the early detection of lung cancer — the leading cause of cancer death in both men and women in the U.S.
Should a more individualized model replace the current method for determining which people should be screened for lung cancer?
A new study found that an alternative model to identify patients with lung cancer eligible for screening was more accurate than the currently used method based on the United States Preventive Services Task Force (USPSTF) criteria.
Dr. Tanya Stoyanova receives Department of Defense award to find new lung cancer treatments
Dr. Tanya Stoyanova, associate professor of molecular and medical pharmacology and urology at the David Geffen School of Medicine at UCLA, was awarded a $350,000 Idea Development Award from the Department of Defense.
Scientists Successfully Maneuver Robot Through Living Lung Tissue
Ron Alterovitz, PhD, in the UNC Computer Science Department, and Jason Akulian, MD MPH, in the UNC School of Medicine, have shown that their steerable lung robot can autonomously maneuver the intricacies of the lung, while avoiding important lung structures.
Combination immunotherapy treatment effective before lung cancer surgery
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), according to researchers at The University of Texas MD Anderson Cancer Center.
Trial: Combination Immunotherapy Prior To Lung Cancer Surgery Appears Promising
Patients with stage 1–3 non-small cell lung cancer (NSCLC) given a combination immunotherapy prior to surgery (neoadjuvant) had a better major pathological response (10% or less residual cancer) when the cancer was removed than those who took a single immunotherapy agent alone, according to results of a novel multicenter phase 2 NeoCOAST platform trial that included two investigators from the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Institute for Cancer Immunotherapy. The results were published online Sept. 14 in Cancer Discovery, a journal of the American Association for Cancer Research.
$50 million gift to expand health sciences research at Virginia Tech
The Richmond, Virginia-based Red Gates Foundation recently committed $50 million to the Fralin Biomedical Research Institute at VTC to accelerate health sciences research at Virginia Tech. The gift is among the largest ever made to the university.
Intensity-modulated radiation therapy provides long-term benefits to patients with locally advanced lung cancer
Intensity-modulated radiation therapy (IMRT) should be the preferred choice when treating patients with locally advanced non-small cell lung cancer (NSCLC), as it reduces radiation exposure to the heart and lungs, according to researchers at The University of Texas MD Anderson Cancer Center.
AI more accurately identifies patients with advanced lung cancer that respond to immunotherapy and helps doctors select treatments
Treatment planning for lung cancer can often be complex due to variations in assessing immune biomarkers. In a new study, Yale Cancer Center researchers at Yale School of Medicine used artificial intelligence (AI) tools and digital pathology to improve the accuracy of this process.
Cancer screenings have saved the U.S. at least $6.5 trillion, study estimates
Americans have gotten at least 12 million more years of life to live because of preventive cancer screenings they’ve gotten the past 25 years, a new study estimates. That adds up to at least $6.5 trillion in added economic impact, because of scans and tests that look for early signs of breast, colon, cervical and lung cancer in adults at the highest risk.
MD Anderson Research Highlights for August 2, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Recent developments include a novel biomarker that may predict the aggressiveness of pancreatic cancer precursors, insights into the structure and function of a breast and ovarian cancer susceptibility gene, a new approach to overcoming treatment resistance in ovarian cancer, distinguishing features of young-onset rectal cancer, a biomarker and potential target for metastatic lung cancer, machine learning models to better predict outcomes of patients with mantle cell lymphoma (MCL), and a promising therapy for patients with relapsed/refractory MCL.
Tiny surgical robots could transform detection and treatment of cancers
The ultra-soft tentacle, which measures just 2 millimetres in diameter and is controlled by magnets, can reach some of the smallest bronchial tubes and could transform the treatment of lung cancer.
Novel Machine Learning Blood Test Detects Cancers with Genome-Wide Mutations in Single Molecules of Cell-Free DNA
Novel blood testing technology being developed by researchers at the Johns Hopkins Kimmel Cancer Center that combines genome-wide sequencing of single molecules of DNA shed from tumors and machine learning may allow earlier detection of lung and other cancers.
Assessment of Lung Cancer Risk Among Smokers for Whom Annual Screening Is Not Recommended
Abstract Importance: The US Preventive Services Task Force does not recommend annual lung cancer screening with low-dose computed tomography (LDCT) for adults aged 50 to 80 years who are former smokers with 20 or more pack-years of smoking who quit 15…
Blood test aids in predicting lung cancer mortality risk
A blood-based four-protein panel (4MP), when combined with a lung cancer risk model (PLCOm2012), can better identify those at high risk of dying from lung cancer than the current U.S. Preventive Services Task Force (USPSTF) criteria.
Pharmacologist: Cancer drug shortage is delaying lifesaving treatments
This year, an estimated 2 million Americans will be diagnosed with cancer. Now, a New York Institute of Technology pharmacology expert contends that these patients’ realities could grow increasingly harsher, as a monthslong shortage of chemotherapy drugs continues. Low supplies of…
Food-Drug Interactions Could be Impactful for Some Lung Cancer Patients According to New Study in JNCCN
New research in the June 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network found that when alectinib—a safe and effective small molecule kinase inhibitor used to treat some types of advanced lung cancer—was taken with a fuller breakfast, or with lunch, it resulted in significantly higher drug concentrations than when taken with a low-fat breakfast.
Osimertinib shows promising phase-3 results for non-small cell lung cancer
Researchers at Yale School of Medicine have presented findings from an international late-stage clinical trial that shows the targeted therapy osimertinib improved rates of survival and reduced risk of recurrence in patients with non-small cell lung cancer following surgery. The…
Real-World Data Suggests Stopping Immunotherapy after Two Years is Reasonable in Patients with Advanced Lung Cancer
A new study from Penn Medicine’s Abramson Cancer Center suggests that it’s reasonable for patients with advanced lung cancer to stop immunotherapy treatment at two years, as long as their cancer hasn’t progressed.
ASCO23: Sylvester Cancer Experts Available for Interviews on a Wide Range of Topics
In addition to presenting Sylvester Comprehensive Cancer Center research findings, Sylvester experts are available at ASCO to share perspectives on a wide variety of topics and studies ranging from breast cancer to sarcoma, prostate cancer, mesothelioma, melanoma, CNS tumors and more.
UChicago Medicine introduces groundbreaking, next-generation robotic technology to combat early lung cancer
The University of Chicago Medicine is the first U.S. hospital to use new, state-of-the-art robotic technology for bronchoscopies that will improve early detection of lung cancer. UChicago Medicine performed its first four successful cases using the Noah Medical Galaxy Robot on May 18, 2023. Each patient returned home the same day after the procedure.
Underused Screening Test Could be Saving More Lives from Lung Cancer
Lung cancer is responsible for more deaths than any other cancer in the country. While using CT scans to screen for lung cancer has been around for about 10 years, experts say this simple test is largely underused. “Unfortunately, many…
Experts Available on Race-Based Risk for Lung Cancer
Are marginalized groups slipping through the cracks when it comes to lung cancer prevention? Pulmonologists looked into this question and will present their conclusions and recommendations in a live-stream Q&A direct from the annual meeting of the American Thoracic Society.
New Study Shows Mortality Rates for All Major Cancers Decreasing Globally, Except Liver Cancer in Men and Lung Cancer in Women
A new study conducted by scientists at the American Cancer Society and Brookdale University Hospital Medical Center reveals recent mortality rates for all major cancers decreased in most of the studied countries except lung cancer in females and liver cancer in males, where increasing rates were observed in most countries. The research also showed that cancer-specific mortality rates varied substantially across countries, with rates of lung and cervical cancer varying by 10-fold. The study was published today in the journal Cancer Epidemiology, Biomarkers & Prevention, a publication of the American Association for Cancer Research.
Immunotherapy plus chemotherapy combination for advanced lung cancer not only prolongs life but also improves its quality
A recent clinical trial showed that the drug combination of cemiplimab plus platinum chemotherapy can prolong survival in patients with advanced lung cancer when compared with placebo plus platinum chemotherapy. Now an analysis published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society, indicates that cemiplimab plus platinum chemotherapy also affects quality of life compared to chemotherapy alone.
Air Quality and Lung Cancer in Wayne County, Mich.—a Large Urban/Suburban Study
Lung cancer is the most common cause of cancer-related deaths in North America. Although cigarette smoking remains the main risk factor for lung cancer development, the importance of environmental factors such as pollution and poor air quality is becoming increasingly recognized.
MD Anderson and Generate:Biomedicines enter co-development and commercialization agreement to accelerate novel protein therapeutics for oncology using generative AI
MD Anderson and Generate:Biomedicines announced a co-development and commercialization agreement to accelerate novel protein therapies using generative AI.
New CAR T-Cell Strategy Highly Effective Against Small Cell Lung Cancer in Preclinical Study
A new approach to chimeric antigen receptor T-cell (CAR T) therapy has shown great promise against small cell lung cancer (SCLC) in a preclinical study. The findings cover new ground in our understanding of how CAR T can be employed against solid-tumor cancers, and provide support for further studies in cancer patients.
“Radon”: a Lung Cancer Threat Next Door – Chula’s Engineering Professor Suggests Ways to Protect Ourselves
Radon is a radioactive element naturally found in rocks, soil, sand, and water, which humans generally use in construction. This dangerous gas is second only to smoking in contributing to lung cancer. A Chula engineering professor suggests ways to defend ourselves from this threat.
New Lung Immuno-oncology Therapeutic Strategy Identified
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated in a preclinical study a potential new therapeutic approach to treating the most common form of lung cancer. The strategy involves inhibiting the immune-system molecule TREM2 while enhancing natural killer cells (the so-called protectors of the immune system). It was described in the April 20 online issue of Nature Immunology.
Wake Forest University School of Medicine Receives $2.7 Million Grant from National Cancer Institute to Study Lung Cancer Disparities
Wake Forest University School of Medicine has been awarded a five-year, $2.7 million grant from the National Cancer Institute to investigate lung cancer health disparities. Researchers will focus on developing novel treatments that target genetic, immunologic and metabolic changes that disproportionally affect Black patients with non-small cell lung cancer (NSCLC).